Samsung Biologics Signs 400.7 Billion KRW Drug Manufacturing Contract Increase with European Pharma

Samsung Biologics announced on June 9, 2026 a correction disclosure increasing its drug manufacturing contract with a European pharmaceutical company from 349.9 billion KRW to 400.7 billion KRW, an increase of 50.8 billion KRW.
The contract period runs from July 31, 2025 to March 13, 2032. The increase was requested by the client, and the total amount is USD 270.79 million based on the initial exchange rate of 1479.80 KRW per USD.
The contract value represents 8.81% of 2024 consolidated revenue of 4.5473 trillion KRW, with no upfront payment. The counterparty name will remain undisclosed until March 13, 2032 due to business confidentiality.
[AI Summary]This contract increase demonstrates Samsung Biologics' competitiveness in biopharmaceutical CDMO and supports stable revenue growth. However, undisclosed counterparty and long-term conditions warrant investor monitoring.